<DOC>
	<DOC>NCT00567671</DOC>
	<brief_summary>Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.</brief_summary>
	<brief_title>Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia</brief_title>
	<detailed_description>Subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is performed as a single treatment. Subjects are followed for at least 12 months to evaluate the long term effects of corneal collagen cross-linking. Subjects may be referred from other physicians but must return to Emory Vision for completion of all study visits.</detailed_description>
	<mesh_term>Keratoconus</mesh_term>
	<mesh_term>Dilatation, Pathologic</mesh_term>
	<mesh_term>Corneal Diseases</mesh_term>
	<criteria>Diagnosis of keratoconus with documented progression over the previous 12 months. Diagnosis of corneal ectasia Must be able to complete all study visits Prior corneal surgery in the keratoconus group Corneal scarring</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>keratoconus</keyword>
	<keyword>ectasia</keyword>
	<keyword>cross-linking</keyword>
	<keyword>riboflavin</keyword>
	<keyword>UVA light</keyword>
	<keyword>cornea</keyword>
</DOC>